Payment overview · 2025
General Payments
$228.32
11 reported records · 4 companies
Healthcare provider profile · identity verified
Khalid Nur, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PICO RIVERA, CA · NPI 1235147521
Verified facts
What the public records show
CMS Open Payments records show Khalid Nur, M.D. received $228.32 in general payments during 2025 across 11 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 33.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rexulti.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $76.31 | 33.4% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $72.83 | 31.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $57.82 | 25.3% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.36 | 9.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $228.32 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $149.14 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.07 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.36 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 548 | 100 |
| Eliquis | Apixaban | 503 | 43 |
| Xarelto | Rivaroxaban | 352 | 30 |
| Famotidine | Famotidine | 335 | 52 |
| Amlodipine Besylate | Amlodipine Besylate | 320 | 53 |
| Gabapentin | Gabapentin | 315 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 311 | 42 |
| Losartan Potassium | Losartan Potassium | 258 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 254 | 44 |
| Furosemide | Furosemide | 234 | 49 |
| Metformin Hcl | Metformin Hcl | 221 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 211 | 27 |
| Mirtazapine | Mirtazapine | 207 | 37 |
| Donepezil Hcl | Donepezil Hcl | 187 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 183 | 27 |
| Levetiracetam | Levetiracetam | 150 | 17 |
| Omeprazole | Omeprazole | 143 | 22 |
| Carvedilol | Carvedilol | 131 | 28 |
| Glimepiride | Glimepiride | 119 | 15 |
| Finasteride | Finasteride | 108 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 105 | 24 |
| Memantine Hcl | Memantine Hcl | 98 | 14 |
| Lactulose | Lactulose | 97 | 21 |
| Warfarin Sodium | Warfarin Sodium | 89 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 88 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 88 | suppressed |
| Potassium Chloride | Potassium Chloride | 88 | 16 |
| Lisinopril | Lisinopril | 87 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 87 | 23 |
| Simvastatin | Simvastatin | 82 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 14 |
| Glipizide | Glipizide | 81 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 75 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 73 | 12 |
| Sertraline Hcl | Sertraline Hcl | 70 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 19 |
| Humulin R | Insulin Regular, Human | 68 | 17 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 68 | 27 |
| Benazepril Hcl | Benazepril Hcl | 64 | suppressed |
| Baclofen | Baclofen | 57 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 55 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | suppressed |
| Lorazepam | Lorazepam | 54 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 22 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 52 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 51 | suppressed |
| Digoxin | Digoxin | 49 | suppressed |
| Prednisone | Prednisone | 49 | 15 |
| Tradjenta | Linagliptin | 49 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 48 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | suppressed |
| Levemir Flexpen | Insulin Detemir | 48 | suppressed |
| Jardiance | Empagliflozin | 45 | suppressed |
| Lacosamide | Lacosamide | 43 | suppressed |
| Nifedipine Er | Nifedipine | 43 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 42 | 17 |
| Trazodone Hcl | Trazodone Hcl | 42 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 41 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 41 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 40 | suppressed |
| Latanoprost | Latanoprost | 40 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 39 | 15 |
| Ibuprofen | Ibuprofen | 38 | 17 |
| Gemfibrozil | Gemfibrozil | 37 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 36 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 35 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 34 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Rexulti | Brexpiprazole | 34 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Novolog Flexpen | Insulin Aspart | 32 | suppressed |
| Allopurinol | Allopurinol | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 31 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 28 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 27 | 13 |
| Cephalexin | Cephalexin | 26 | 22 |
| Gemtesa | Vibegron | 26 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 11 |
| Nitroglycerin | Nitroglycerin | 24 | 13 |
| Novolin R | Insulin Regular, Human | 24 | suppressed |
| Viokace | Lipase/Protease/Amylase | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 16 |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 11 |
| Calcium Acetate | Calcium Acetate | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 21 | suppressed |
| Levemir | Insulin Detemir | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | suppressed |
| Epogen | Epoetin Alfa | 20 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 20 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 20 | suppressed |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Ertapenem | Ertapenem Sodium | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Rivastigmine | Rivastigmine | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Insulin Lispro | Insulin Lispro | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Repaglinide | Repaglinide | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Glucagon Emergency Kit | Glucagon | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Procrit | Epoetin Alfa | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $228.32 · 11 records | Otsuka America Pharmaceutical, Inc. | Kerendia, Ozempic, REXULTI, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lundbeck LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error